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Sporadic	infection	with	Shiga	toxin–producing	Escheri-
chia coli	(STEC)	in	New	Mexico	increased	from	0.9	cases	
per	100,000	population	(95%	confidence	interval	[CI]	0.5–
1.36)	in	2004	to	1.7	(95%	CI	1.14–2.26)	in	2007.	Non-O157	
STEC	was	more	common	in	nonwhite	residents,	children	<5	
years of age, and urban residents.
T
he epidemiology of infections and hemolytic uremic 
syndrome (HUS) caused by Shiga toxin–producing Es-
cherichia coli (STEC) O157:H7 are well described (1–4). 
Non-O157 STEC infection also is associated with severe 
illness and HUS but often is underdiagnosed and less well 
understood (3–7). Studies in Europe indicate that non-O157 
STEC infections occur more frequently than do STEC O157 
infections (3). STEC O157 infection has been a notifiable 
disease in the United States since 1994, but non-O157 STEC 
infection became reportable only in 2000 (8). To understand 
trends in STEC O157 and non-O157 infections and their 
epidemiology  in  New  Mexico,  we  analyzed  population-
based data from the active surveillance of clinical laborato-
ries. This surveillance was performed as part of the Centers 
for Disease Control and Prevention’s (CDC’s) Foodborne 
Diseases Active Surveillance Network (FoodNet), to which 
New Mexico began contributing data in 2004.
The Study
All STEC isolates or broths were sent for confirmation 
to the Scientific Laboratory Division of the New Mexico 
Department of Health, where Shiga toxin expression was 
confirmed by enzyme immunoassay (EIA); the broth was 
then cultured and preliminarily serotyped. Pulsed-field gel 
electrophoresis was performed on all isolates. The labora-
tory submitted non-O157 STEC isolates to CDC for addi-
tional serotyping and PCR testing for toxin genes.
This analysis comprised only sporadic cases of STEC. 
Negative  binomial  regression  models  were  used  to  cal-
culate incidence rates and assess differences in risks for 
STEC O157 and non-O157 infections. Variables were re-
porting year, patient age, race/ethnicity, sex, and rural ver-
sus urban residence (8); p<0.05 was considered statistically 
significant.
During 2004–2007, New Mexico FoodNet identified 
111 cases of laboratory-confirmed sporadic STEC infection; 
40 (36%) were STEC O157, and 71 (64%) were non-O157 
STEC (Table 1). Six additional cases were outbreak associ-
ated. Incidence increased from 0.93 cases per 100,000 pop-
ulation (95% confidence interval [CI] 0.5–1.36) in 2004 to 
1.07 per 100,000 (95% CI 0.61–1.52) in 2005 and 1.84 per 
100,000 (95% CI 1.25–2.44) in 2006. The rate fell slightly 
in 2007, to 1.70 per 100,000 (95% CI 1.14–2.26) popula-
tion, resulting in a test of trend that approached statistical 
significance (p = 0.09). From 2004 through 2007, sporadic 
STEC infections increased 94%. A total of 18 STEC se-
rotypes were identified during this time. The primary se-
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Table 1. Demographic characteristics of case-patients who had 
laboratory-confirmed	STEC	infections,	New	Mexico,	USA,	2004–
2007*
No.	case-patients	
Characteristic
O157
STEC
Non-O157	
STEC Total 
Age	group,	y†	
  <1  3 3 6
  1–4  3 26 29
	 5–10	 10 7 17
  11–18  4 12 16
	 19–29	 5 7 12
	 30–39	 4 2 6
	 40	–49	 1 2 3
	 50–59	 1 5 6
>60 9 7 16
Sex	
  Male  18 34 52
	 Female	 22 37 59
Race/ethnicity	
	 White	non-Hispanic		 17 17 34
	 White	Hispanic	 11 12 23
	 White,	unknown	ethnicity	 5 4 9
	 Native	American	 3 10 13
	 African	American	 1 0 1
  Other  0 5 5
	 Unknown	 3 23 26
Type of county 
  Urban  29 64 93
	 Rural	 11 7 18
Year of diagnosis 
  2004  7 11 18
	 2005	 10 11 21
  2006  14 23 37
  2007  9 26 35
Total no. case-patients  40 71 111
*STEC,	Shiga	toxin–producing	Escherichia coli;	O157,	serotype	O157:H7.
†Median	age	(range)	of	patients:	STEC	O157–infected,	18	y	(4	mo–78	y);	
non-O157	STEC–infected,	10	y	(5	mo–70	y);	total,	13.3	y	(4	mo–78	y).rotypes  responsible  for  the  increase  were  STEC  O157, 
O26, O111, and O103, constituting 75% of all STEC cases 
reported. Incidences of STEC serotypes O26, O111, and 
O103 combined increased 300% from 2004 through 2007. 
The proportion of non-O157 STEC ranged from 52% in 
2005 to 74% in 2007.
Although STEC O157 was the 1 serotype most often 
identified, infections caused by non-O157 STEC (all sero-
types) were diagnosed more frequently. STEC O26 (18%) 
and O111 (13%) were the most commonly identified non-
O157 STEC serotypes. Other STEC O serotypes (O103, 
O121, O46, O177, and O91) were responsible for 33% of 
all STEC infections. Most isolates were positive for toxin 
gene stx1 (86%), intimin (66%), and enterohemolysin A 
(81%).
STEC O157 infection was significantly more likely to 
be diagnosed in adults (half of all cases, one third of non-
O157 STEC cases) than in children (<18 years of age) (p 
= 0.01). Non-O157 STEC serotypes were most commonly 
identified in children 1–4 years of age. STEC O157 infec-
tions occurred most commonly in children 5–10 years of 
age, followed by adults >60 years. Sex distributions were 
similar for patients with STEC O157 and non-O157 infec-
tions (55% female vs. 45% male and 52% vs. 48%, respec-
tively). White non-Hispanics, which constitute 43% of New 
Mexico’s population, made up 31% of all confirmed STEC 
infections in New Mexico; white Hispanics (42%) made 
up 21% of confirmed STEC cases; and Native Americans 
(10%) made up 12% of cases (Table 1).
More laboratory-confirmed STEC infections were di-
agnosed during the summer months than during the rest of 
the year. STEC O157 cases were diagnosed more frequent-
ly in September (10 cases); non-O157 STEC cases were 
most frequently diagnosed in June and July (9 cases each).
Although  STEC  O157  infections  was  diagnosed  in 
more persons than were non-O157 STEC infections (28% 
vs. 16%), the difference was not significant. Patients with 
STEC O157 infections stayed in the hospital a mean of 6 
days (median 4), compared with a mean of 4.5 days (me-
dian 3) for patients with non-O157 STEC infections, also 
not significant. All 5 reported cases of HUS were caused 
by STEC O157.
International  travel  was  related  to  STEC  infection 
for 12 (11%) patients. Two (5%) STEC O157 cases were 
travel related, as were 4 (10%) cases each of STEC O111 
and O26; and 1 (1%) case each of STEC O128 and O103. 
Travel to Mexico was documented for 10 of the 12 travel-
associated cases.
Most (99 [89%]) persons with STEC were from New 
Mexico’s urban counties. We calculated incidence rate ra-
tios between STEC O157 and non-O157 infections during 
2004–2007  (Table  2),  while  adjusting  for  variables  that 
were  significant  in  negative  binomial  models,  including 
race (white non-Hispanic vs. nonwhite), age (<5 years vs. 
>5 years), and county (urban vs. rural). More patients with 
non-O157 STEC infection during this time were nonwhite, 
<5 years of age, and residents of urban counties. Patients 
infected with STEC O157 were more likely to be white 
non-Hispanic, >5 years of age, and residents of rural coun-
ties.
Conclusions
The data collected by New Mexico’s FoodNet surveil-
lance network indicate that sporadic STEC cases increased 
substantially from 2004 through 2007. Reports of STEC 
O157 infection doubled from 7 to 14 from 2004 to 2006 but 
dropped to 9 in 2007. However, the number of non-O157 
STEC cases continued to climb and accounted for most of 
the increase in overall STEC rates in New Mexico during 
this time, similar to rates in Connecticut and other FoodNet 
sites (4,9).
Non-O157 STEC infections ranged from 52% to 74% 
of all Shiga toxin–positive cases diagnosed each year and 
64% of all identified STEC cases. New Mexico was sec-
ond only to Colorado (2.12 cases per 100,000 population) 
among  FoodNet  sites  for  non-O157  STEC  incidence  in 
2007 (10). Similar to serotypes reported from other loca-
tions, STEC serotypes O26, O111, and O103 made up most 
non-O157 infections in New Mexico (1), especially O26 
and O111 (18% and 13% of all cases, respectively).
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Table	2.	Comparisons	of	risk	for	infection	with	STEC	O157	versus	non-O157	STEC	types,	by	demographic characteristic, averaged 
population,	New	Mexico,	USA,	2004–2007*	
Characteristic Unadjusted	incidence	rate	ratio†	(95%	CI) p value Adjusted	incidence	rate	ratio†	(95%	CI) p value
Race
  Other 1 1
  White 3.21 (1.42–7.27) 0.01 3.03	(1.34–6.90) 0.008
Age,	y
	 <5 1 1
>5 2.61	(1.09–6.22) 0.03 2.74	(1.15–6.54) 0.031
County
  Urban 1 1
	 Rural 1.96	(0.98–3.92) 0.05 1.84	(0.91–3.69) 0.089
*STEC,	Shiga	toxin–producing	Escherichia coli;	O157,	serotype	O157:H7;	CI,	confidence	interval.	
†Corrected	for	overdispersion	by	using	negative	binomial	distribution.	Shiga	Toxin–producing	E. coli
As  previously  reported  (1),  non-O157  STEC  infec-
tions occurred commonly in young children in this study. 
They also occurred at a higher rate for non-white New 
Mexico  residents.  Another  recent  study  similarly  found 
higher shigellosis rates in counties with higher proportions 
of Hispanics (11). This study concurs with others that have 
reported finding the highest rates of STEC O157 rates in 
rural communities (with increased opportunities for animal 
contact) and in the West (12,13).
Year-to-year increases in numbers of non-O157 STEC 
infections, both nationally and in New Mexico, must be 
interpreted with caution because of changes in laboratory 
testing practices. Although the state’s largest clinical labo-
ratory performed EIAs before active surveillance was im-
plemented in 2004, other laboratories throughout the state 
might have changed their testing practices.
Risk factors for non-O157 STEC infections may be 
similar to those for STEC O157 infections (9), but addi-
tional studies are needed to elucidate differences and simi-
larities between them, as well as among non-O157 STEC 
serotypes (14). Clinical laboratories should simultaneously 
screen for Shiga toxin and culture all positive isolates to de-
termine the true incidence of non-O157 STEC infections.
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